Cartesian Therapeutics (RNAC) Equity Ratio (2016 - 2025)
Historic Equity Ratio for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to 0.1.
- Cartesian Therapeutics' Equity Ratio fell 592346.25% to 0.1 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.1, marking a year-over-year decrease of 592346.25%. This contributed to the annual value of 0.02 for FY2024, which is 9891.64% up from last year.
- As of Q3 2025, Cartesian Therapeutics' Equity Ratio stood at 0.1, which was down 592346.25% from 0.01 recorded in Q2 2025.
- In the past 5 years, Cartesian Therapeutics' Equity Ratio registered a high of 0.57 during Q3 2023, and its lowest value of 1.44 during Q4 2023.
- In the last 5 years, Cartesian Therapeutics' Equity Ratio had a median value of 0.01 in 2025 and averaged 0.06.
- Per our database at Business Quant, Cartesian Therapeutics' Equity Ratio skyrocketed by 213720.2% in 2022 and then crashed by 592346.25% in 2025.
- Cartesian Therapeutics' Equity Ratio (Quarter) stood at 0.14 in 2021, then soared by 301.55% to 0.57 in 2022, then crashed by 355.12% to 1.44 in 2023, then soared by 98.92% to 0.02 in 2024, then tumbled by 515.12% to 0.1 in 2025.
- Its Equity Ratio was 0.1 in Q3 2025, compared to 0.01 in Q2 2025 and 0.05 in Q1 2025.